Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases... Show more
DYN is expected to report earnings to fall 2.98% to -85 cents per share on May 01
Q1'25
Est.
$-0.85
Q4'24
Beat
by $0.06
Q3'24
Missed
by $0.25
Q2'24
Beat
by $0.02
Q1'24
Missed
by $0.02
The last earnings report on February 27 showed earnings per share of -87 cents, beating the estimate of -93 cents. With 1.70M shares outstanding, the current market capitalization sits at 1.07B.